Woody Sherman

Chief Innovation Officer @PsiThera

Boston, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2025 — Present

Chief Innovation Officer @PsiThera

View department →

Boston, MA, US

EDUCATION

1995 — 1999

UC Santa Barbara

BS, Physical Chemistry

1995 — 1999

UC Santa Barbara

BA, Creative Studies

1999 — 2004

Massachusetts Institute of Technology

PhD, Physical Chemistry

SKILLS

GenomicsDockingBiochemistryMolecular DynamicsDrug DiscoveryOrganic ChemistryPharmacophore ModelingData MiningMedicinal ChemistryScienceComputational BiologyComputational ChemistryDrug DevelopmentCheminformaticsBioinformaticsBiotechnologyMolecular ModelingChemistryPhysical ChemistryProtein ChemistryDrug DesignVirtual ScreeningLibraryLibrary DesignQsarHomology ModelingBiophysicsAntibodiesLead OptimizationStructural BioinformaticsLead Change

ABOUT WOODY SHERMAN

Woody Sherman is the Founder and Chief Innovation Officer of PsiThera, where he leads the development of a computational-first drug discovery platform advancing oral small-molecule medicines for high-value immunology and inflammation targets traditionally addressed by biologics. He is also Chair of the OpenFold Consortium Executive Committee, guiding a global open science effort to build next-generation foundation models for biomolecular structure and drug design that are shaping the future of the field.Across industry and academia, Woody has been a pioneer in applying physics-based simulation, AI/ML, and integrated experimental-computational workflows to solve real-world drug discovery problems. His career spans leadership roles as Chief Computational Scientist at Roivant Sciences, Chief Scientific Officer at Silicon Therapeutics, and Global Head of Applications Science at Schrödinger, where he helped translate advanced modeling technologies into widely adopted discovery tools.Woody has authored over 100 peer-reviewed publications spanning molecular simulation, free energy methods, protein structure and dynamics, machine learning, and structure-based drug design, and is an Adjunct Professor at the University of Massachusetts Amherst. His work bridges deep technical innovation with strategic vision for how computational technologies can materially transform the speed, cost, and probability of success in drug discovery.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.